We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

107 hedge funds and large institutions have $210M invested in Rigel Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 31 increasing their positions, 42 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

8.92% more ownership

Funds ownership: 0% → 8.92% (+8.9%)

12% less funds holding

Funds holding: 121 → 107 (-14)

23% less call options, than puts

Call options by funds: $202K | Put options by funds: $262K

26% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 42

33% less capital invested

Capital invested by funds: $316M → $210M (-$105M)

48% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 27

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
107
Holders Change
-14
Holders Change %
-11.57%
% of All Funds
2.67%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
14
Increased
31
Reduced
42
Closed
27
Calls
$202K
Puts
$262K
Net Calls
-$60K
Net Calls Change
-$2.04M

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$16.5M
2
BBA
Baker Bros. Advisors
New York
+$5.78M
3
CAM
Cormorant Asset Management
Massachusetts
+$4.91M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$2.12M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.87M

Top Sellers

1
BC
Boxer Capital
California
-$4.96M
2
SAM
Senzar Asset Management
New York
-$3.33M
3
Goldman Sachs
Goldman Sachs
New York
-$3.3M
4
PAI
Palo Alto Investors
California
-$2.89M
5
EI
EAM Investors
California
-$2.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
GTC
26
Ghost Tree Capital
New York
$1.67M – – –
Morgan Stanley
27
Morgan Stanley
New York
$1.64M +$1.84M +64,080 +1,302%
CS
28
Credit Suisse
Switzerland
$1.55M +$1.28M +44,609 +219%
Goldman Sachs
29
Goldman Sachs
New York
$1.47M -$3.3M -115,228 -65%
CS
30
Candriam SCA
Luxembourg
$1.46M -$315K -11,000 -15%
Deutsche Bank
31
Deutsche Bank
Germany
$1.42M +$964K +33,652 +129%
Jacobs Levy Equity Management
32
Jacobs Levy Equity Management
New Jersey
$1.36M -$203K -7,090 -11%
TCIM
33
TIAA CREF Investment Management
New York
$1.15M -$778K -27,159 -36%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$1.06M +$52K +1,814 +4%
PC
35
Paulson & Co
New York
$923K -$1.2M -41,730 -52%
BA
36
BlackRock Advisors
Delaware
$893K -$24.1K -843 -2%
BIM
37
BlackRock Investment Management
Delaware
$891K -$1.83K -64 -0.2%
Bank of America
38
Bank of America
North Carolina
$850K +$586K +20,465 +134%
NSEDCP
39
NJ State Employees Deferred Compensation Plan
New Jersey
$845K – – –
Citigroup
40
Citigroup
New York
$808K +$627K +21,888 +181%
NFA
41
Nationwide Fund Advisors
Ohio
$781K -$22.6K -790 -2%
USAA
42
United Services Automobile Association
Texas
$764K +$534K +18,644 +139%
Connor, Clark & Lunn Investment Management (CC&L)
43
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$550K -$255K -8,920 -28%
Susquehanna International Group
44
Susquehanna International Group
Pennsylvania
$529K +$457K +15,941 +254%
TA
45
Teachers Advisors
New York
$508K +$126K +4,397 +26%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$491K +$27.2K +950 +5%
Charles Schwab
47
Charles Schwab
California
$480K – – –
Two Sigma Advisers
48
Two Sigma Advisers
New York
$474K -$212K -7,390 -27%
Russell Investments Group
49
Russell Investments Group
United Kingdom
$459K +$546K +19,075 New
AIM
50
Alambic Investment Management
California
$454K +$66.2K +2,310 +14%
1
2
3 4 5

RIGL Hedge Fund Activity: Q4 2016 in Review

107 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2016, worth a combined $210M — down 33% from $316M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of RIGL and 14 opened new positions — a net loss of 13 holders — while 42 trimmed existing stakes and 31 added.

The largest buyer was Wellington Management Group, adding an estimated $16.5M. The largest seller was Boxer Capital, exiting entirely with an estimated $4.96M sold.

  • 107 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2016, down from 121 in Q3 2016.
  • Funds reported $210M of Rigel Pharmaceuticals stock for Q4 2016, down 33% quarter-over-quarter.
  • 14 funds opened new Rigel Pharmaceuticals positions in Q4 2016 and 27 closed out, a net change of -13 holders.
  • The largest Rigel Pharmaceuticals buyer in Q4 2016 was Wellington Management Group, an estimated $16.5M added.
  • The largest Rigel Pharmaceuticals seller in Q4 2016 was Boxer Capital, an estimated $4.96M sold.

Based on aggregated 13F filings for Q4 2016.